Perioperative management of ophthalmic patients on antithrombotic therapy

The large majority of elderly patients undergoing ophthalmic surgery take antiplatelet and anticoagulant drugs on a regular basis. Antithrombotic treatments predisposes to bleeding complications that may lead to retrobulbar haemorrhage, suprachoroidal haemorrhage and ultimately, to loss of vision. H...

Full description

Bibliographic Details
Main Authors: Jin Yan, Li Wang, Yang Yang
Format: Article
Language:English
Published: Press of International Journal of Ophthalmology (IJO PRESS) 2015-07-01
Series:Guoji Yanke Zazhi
Subjects:
Online Access:http://ies.ijo.cn/cn_publish/2015/7/201507019.pdf
id doaj-660131bfc6034b4aa2821b37c3036b57
record_format Article
spelling doaj-660131bfc6034b4aa2821b37c3036b572020-11-24T23:13:52ZengPress of International Journal of Ophthalmology (IJO PRESS)Guoji Yanke Zazhi1672-51231672-51232015-07-011571190119310.3980/j.issn.1672-5123.2015.7.19Perioperative management of ophthalmic patients on antithrombotic therapyJin Yan0Li Wang1Yang Yang2Ophthalmology Medical Teaching and Research Section,Xi'an Medical University, Xi'an 710021, Shaanxi Province, ChinaOphthalmology Medical Teaching and Research Section,Xi'an Medical University, Xi'an 710021, Shaanxi Province, ChinaOphthalmology Medical Teaching and Research Section,Xi'an Medical University, Xi'an 710021, Shaanxi Province, ChinaThe large majority of elderly patients undergoing ophthalmic surgery take antiplatelet and anticoagulant drugs on a regular basis. Antithrombotic treatments predisposes to bleeding complications that may lead to retrobulbar haemorrhage, suprachoroidal haemorrhage and ultimately, to loss of vision. However, discontinuation of antithrombotic medication in such patients may lead to thromboembolic events with serious consequences. There are no guidelines on perioperative management of ophthalmic patients who are on antiplatelet and anticoagulant drugs. We reviewed traditional and newer agents in the context of cataract, vitreoretinal, glaucoma and oculoplastic surgery. Recommendations are given for continuation, cessation and recommencement of these agents in order to minimise the risk of bleeding and thrombotic complications.http://ies.ijo.cn/cn_publish/2015/7/201507019.pdfantiplatelet agentsperioperative managementanticoagulantsophthalmic surgery
collection DOAJ
language English
format Article
sources DOAJ
author Jin Yan
Li Wang
Yang Yang
spellingShingle Jin Yan
Li Wang
Yang Yang
Perioperative management of ophthalmic patients on antithrombotic therapy
Guoji Yanke Zazhi
antiplatelet agents
perioperative management
anticoagulants
ophthalmic surgery
author_facet Jin Yan
Li Wang
Yang Yang
author_sort Jin Yan
title Perioperative management of ophthalmic patients on antithrombotic therapy
title_short Perioperative management of ophthalmic patients on antithrombotic therapy
title_full Perioperative management of ophthalmic patients on antithrombotic therapy
title_fullStr Perioperative management of ophthalmic patients on antithrombotic therapy
title_full_unstemmed Perioperative management of ophthalmic patients on antithrombotic therapy
title_sort perioperative management of ophthalmic patients on antithrombotic therapy
publisher Press of International Journal of Ophthalmology (IJO PRESS)
series Guoji Yanke Zazhi
issn 1672-5123
1672-5123
publishDate 2015-07-01
description The large majority of elderly patients undergoing ophthalmic surgery take antiplatelet and anticoagulant drugs on a regular basis. Antithrombotic treatments predisposes to bleeding complications that may lead to retrobulbar haemorrhage, suprachoroidal haemorrhage and ultimately, to loss of vision. However, discontinuation of antithrombotic medication in such patients may lead to thromboembolic events with serious consequences. There are no guidelines on perioperative management of ophthalmic patients who are on antiplatelet and anticoagulant drugs. We reviewed traditional and newer agents in the context of cataract, vitreoretinal, glaucoma and oculoplastic surgery. Recommendations are given for continuation, cessation and recommencement of these agents in order to minimise the risk of bleeding and thrombotic complications.
topic antiplatelet agents
perioperative management
anticoagulants
ophthalmic surgery
url http://ies.ijo.cn/cn_publish/2015/7/201507019.pdf
work_keys_str_mv AT jinyan perioperativemanagementofophthalmicpatientsonantithrombotictherapy
AT liwang perioperativemanagementofophthalmicpatientsonantithrombotictherapy
AT yangyang perioperativemanagementofophthalmicpatientsonantithrombotictherapy
_version_ 1725596368040361984